We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Julia
Borella
julia.borella21@ic.ac.uk
Kaarin
Sabad
ksabad@ic.ac.uk
Kaarin
Sabad
ksabad@ic.ac.uk
Nir
Grossman
nirg@ic.ac.uk
Other degenerative diseases of the nervous systemOrganic, including symptomatic, mental disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The most common brain disorders with age are neurodegenerative diseases such as Alzheimer’s disease (AD). AD leads to cognitive impairment that progressively affects activities of daily living, erodes independence and impairs quality of life. AD and many other neurodegenerative diseases are neither preventable nor curable.
The progression of neurodegenerative diseases involves impairment of bioenergetic processes that are essential for the survival of brain cells. Recent evidence shows that neurodegenerative diseases also involve abnormal neural activity, particularly in deep brain structures, at very early stages. The relationship between abnormal neural activity and impaired bioenergetic processes that promote neurodegeneration, as well as their association with cognitive impairment, are unknown.
This research aims to address this knowledge gap to provide key mechanistic insight into the progression of neurodegenerative diseases such as AD and pave the way to new interventional strategies.
To achieve this aim, we will modulate the neural activity at brain regions that are affected at the early stage of the disease measure, again non-invasively, the induced changes in neural activity its effect on local bioenergetic processes. In addition, we will explore the effect on cognitive performance.
The study will be taking place at the Hammersmith Hospital and will last for five years. It will involve patients with suspected/confirmed early-stage of neurodegeneration.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. Candidate is deemed by the investigator to be unable to provide informed consent. 2. Medical or psychiatric illness that would interfere in completing assessments or impair the safety of the subject for brain stimulation. Such illness includes but is not limited to epilepsy, brain tumour, intracranial infection and psychotic illness. 3. A known genetic mutation associated with familial Alzheimer’s disease or any other autosomal dominant form of dementia. 4. Any contraindication to MRI as determined by screening and safety questionnaire including but not limited to cardiac pacemakers, aneurysm clips, cochlear implants and other ferromagnetic foreign bodies. History of claustrophobia or the inability to tolerate MRI scanning. 5. Ongoing treatment with medication that, in the opinion of the investigator, will compromise subject safety or the scientific integrity of the study. 6. For PET, the candidate has a history of prior radiation exposure for research purposes such that participation in this study would result in ionizing radiation exposure of > 10mSv in the past year, in addition to the normal background exposure. 7. History of drug or allergy that, in the opinion of the investigators, may put the subject at risk through participation. 8. Where participation in the study would result in a donation of blood or blood products in excess of 500 ml within a period of 56 days. 9. History or presence of comorbid neurological diagnoses, not limited to but including, for example, space-occupying lesions, multiple sclerosis, that may influence the outcome or analysis of the scan results. 10. History of clinically significant head injury (e.g., craniotomy, requiring medical or surgical intervention). 11. A screening ECG outside the normal range. 12. Pulse rate < 40 or > 110 BPM or systolic blood pressure > 150 and < 100 or a diastolic blood pressure > 100 and < 60. 13. Abnormal Allen’s test and/or prolonged Prothrombin Time. 14. Needle phobia. 15. Symptoms of coronavirus (COVID-19) infection, including fever, dry cough, sore throat, diarrhoea, and loss of taste or smell.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Nir
Grossman
nirg@ic.ac.uk
Julia
Borella
julia.borella21@ic.ac.uk
Kaarin
Sabad
ksabad@ic.ac.uk
Kaarin
Sabad
ksabad@ic.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by Alzheimer's Association (USA); Medical Research Council (MRC); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 48771
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
